PFIZER INC Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax
PFIZER INC (PFE) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax of $121.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax · last filed 2026-08-04
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2026-06-28 was $121.00M.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2026-03-29 was -$36.00M.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2025-12-31 was $184.00M, a 59.83% decline year-over-year.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for the quarter ending 2025-09-28 was -$1.00M.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2025 was -$212.00M, a 142.48% decline from fiscal 2024.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2024 was $499.00M, a 20.29% decline from fiscal 2023.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2023 was $626.00M, a 56.65% decline from fiscal 2022.
- PFIZER INC other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax for fiscal 2022 was $1.44B, a 174.52% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2026-06-28 | $121.00M 10-Q · filed 2026-08-04 | $85.00M 10-Q · filed 2026-08-04 | $269.00M derived: sum of 3 quarters · filed 2026-08-04 | $268.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-29 | -$36.00M 10-Q · filed 2026-05-05 | $148.00M derived: sum of 2 quarters · filed 2026-05-05 | $147.00M derived: sum of 3 quarters · filed 2026-05-05 | -$126.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $184.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $183.00M derived: sum of 2 quarters · filed 2026-02-26 | -$90.00M derived: sum of 3 quarters · filed 2026-08-04 | -$212.00M 10-K · filed 2026-02-26 |
| 2025-09-28 | -$1.00M 10-Q · filed 2025-11-04 | -$274.00M derived: sum of 2 quarters · filed 2026-08-04 | -$396.00M 10-Q · filed 2025-11-04 | $61.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-29 | -$273.00M 10-Q · filed 2026-08-04 | -$395.00M 10-Q · filed 2026-08-04 | $62.00M derived: sum of 3 quarters · filed 2026-08-04 | -$241.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-30 | -$123.00M 10-Q · filed 2026-05-05 | $335.00M derived: sum of 2 quarters · filed 2026-05-05 | $32.00M derived: sum of 3 quarters · filed 2026-05-05 | $159.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $458.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $155.00M derived: sum of 2 quarters · filed 2026-02-26 | $282.00M derived: sum of 3 quarters · filed 2026-02-26 | $499.00M 10-K · filed 2026-02-26 |
| 2024-09-29 | -$303.00M 10-Q · filed 2025-11-04 | -$176.00M derived: sum of 2 quarters · filed 2025-11-04 | $41.00M 10-Q · filed 2025-11-04 | $148.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $127.00M 10-Q · filed 2025-08-05 | $343.00M 10-Q · filed 2025-08-05 | $451.00M derived: sum of 3 quarters · filed 2026-02-26 | $859.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $217.00M 10-Q · filed 2025-05-05 | $324.00M derived: sum of 2 quarters · filed 2026-02-26 | $732.00M derived: sum of 3 quarters · filed 2026-02-26 | $841.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $107.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $515.00M derived: sum of 2 quarters · filed 2026-02-26 | $624.00M derived: sum of 3 quarters · filed 2026-02-26 | $626.00M 10-K · filed 2026-02-26 |
| 2023-10-01 | $408.00M 10-Q · filed 2024-11-04 | $517.00M derived: sum of 2 quarters · filed 2024-11-04 | $519.00M 10-Q · filed 2024-11-04 | $520.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $109.00M 10-Q · filed 2024-08-05 | $112.00M 10-Q · filed 2024-08-05 | $112.00M derived: sum of 3 quarters · filed 2025-02-27 | $701.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $2.00M 10-Q · filed 2024-05-08 | $3.00M derived: sum of 2 quarters · filed 2025-02-27 | $592.00M derived: sum of 3 quarters · filed 2025-02-27 | $1.24B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $590.00M derived: sum of 2 quarters · filed 2025-02-27 | $1.24B derived: sum of 3 quarters · filed 2025-02-27 | $1.44B 10-K · filed 2025-02-27 |
| 2022-10-02 | $589.00M 10-Q · filed 2023-11-08 | $1.24B derived: sum of 2 quarters · filed 2023-11-08 | $1.44B 10-Q · filed 2023-11-08 | $1.79B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-07-03 | $651.00M 10-Q · filed 2023-08-09 | $854.00M 10-Q · filed 2023-08-09 | $1.20B derived: sum of 3 quarters · filed 2024-02-22 | $1.41B derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-04-03 | $203.00M 10-Q · filed 2023-05-10 | $550.00M derived: sum of 2 quarters · filed 2024-02-22 | $763.00M derived: sum of 3 quarters · filed 2024-02-22 | $515.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $347.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $560.00M derived: sum of 2 quarters · filed 2024-02-22 | $312.00M derived: sum of 3 quarters · filed 2024-02-22 | $526.00M 10-K · filed 2024-02-22 |
| 2021-10-03 | $213.00M 10-Q · filed 2022-11-09 | -$35.00M derived: sum of 2 quarters · filed 2022-11-09 | $179.00M 10-Q · filed 2022-11-09 | $258.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-07-04 | -$248.00M 10-Q · filed 2022-08-10 | -$35.00M 10-Q · filed 2022-08-10 | $45.00M derived: sum of 3 quarters · filed 2023-02-23 | -$327.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-04-04 | $214.00M 10-Q · filed 2022-05-11 | $293.00M derived: sum of 2 quarters · filed 2023-02-23 | -$79.00M derived: sum of 3 quarters · filed 2023-02-23 | $134.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$293.00M derived: sum of 2 quarters · filed 2023-02-23 | -$80.00M derived: sum of 3 quarters · filed 2023-02-23 | -$582.00M 10-K · filed 2023-02-23 |
| 2020-09-27 | -$372.00M 10-Q · filed 2021-11-12 | -$159.00M derived: sum of 2 quarters · filed 2021-11-12 | -$661.00M 10-Q · filed 2021-11-12 | -$425.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-28 | $213.00M 10-Q · filed 2021-08-12 | -$288.00M 10-Q · filed 2021-08-12 | -$53.00M derived: sum of 3 quarters · filed 2022-02-24 | $97.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-29 | -$501.00M 10-Q · filed 2021-05-13 | -$266.00M derived: sum of 2 quarters · filed 2022-02-24 | -$116.00M derived: sum of 3 quarters · filed 2022-02-24 | -$292.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $235.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $385.00M derived: sum of 2 quarters · filed 2022-02-24 | $209.00M derived: sum of 3 quarters · filed 2022-02-24 | $476.00M 10-K · filed 2022-02-24 |
| 2019-09-29 | $150.00M 10-Q · filed 2020-11-05 | -$26.00M derived: sum of 2 quarters · filed 2020-11-05 | $241.00M 10-Q · filed 2020-11-05 | $225.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$176.00M 10-Q · filed 2020-08-06 | $91.00M 10-Q · filed 2020-08-06 | $75.00M derived: sum of 3 quarters · filed 2021-02-25 | $297.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $267.00M 10-Q · filed 2020-05-07 | $251.00M derived: sum of 2 quarters · filed 2021-02-25 | $473.00M derived: sum of 3 quarters · filed 2021-02-25 | $600.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $206.00M derived: sum of 2 quarters · filed 2021-02-25 | $333.00M derived: sum of 3 quarters · filed 2021-02-25 | $220.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $222.00M 10-Q · filed 2019-11-07 | $349.00M derived: sum of 2 quarters · filed 2019-11-07 | $236.00M 10-Q · filed 2019-11-07 | $374.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-07-01 | $127.00M 10-Q · filed 2019-08-08 | $13.00M 10-Q · filed 2019-08-08 | $152.00M derived: sum of 3 quarters · filed 2020-02-27 | $102.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-04-01 | -$114.00M 10-Q · filed 2019-05-09 | $25.00M derived: sum of 2 quarters · filed 2020-02-27 | -$25.00M derived: sum of 3 quarters · filed 2020-02-27 | -$115.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $89.00M derived: sum of 2 quarters · filed 2020-02-27 | -$1.00M derived: sum of 3 quarters · filed 2020-02-27 | -$10.00M 10-K · filed 2020-02-27 |
| 2017-10-01 | -$50.00M 10-Q · filed 2018-11-08 | -$140.00M derived: sum of 2 quarters · filed 2018-11-08 | -$149.00M 10-Q · filed 2018-11-08 | |
| 2017-07-02 | -$90.00M 10-Q · filed 2018-08-09 | -$99.00M 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | -$442.00M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |